Solid Omental Tumors Treatment & Management
- Author: Kendrix J Evans, MD, MS; Chief Editor: John Geibel, MD, DSc, MSc, MA more...
The rarity of primary omental tumors hinders adequate assessment of adjuvant therapy. Some reports have suggested that chemotherapy may be effective.
In the treatment of malignant hemangiopericytoma, several groups have observed that doxorubicin, either alone or in conjunction with other agents, can achieve response rates of up to 80%. A 12-month course of adjuvant chemotherapy with doxorubicin, cytotoxin, and dimethyltriazenoimidazolecarboxamide (DTIC) has been suggested for the treatment of fibrosarcoma. In treating leiomyosarcoma, combination chemotherapy with hydroxyurea, etoposide, and dacarbazine has been used. Other agents used include intraperitoneal cisplatin with intravenous administration of ifosfamide and pirarubicin hydrochloride.
Radiotherapy is reportedly effective for partially excised tumors or inoperable tumors. In one study, 50 Gy was used to treat a partially excised liposarcoma. The tumor recurred after several months, necessitating a further debulking operation. The benefits of radiotherapy must be weighed against the risk of injury to abdominal viscera, particularly the bowel.
For treatment of gastrointestinal (GI) stromal tumors (GISTs), which are refractory to standard chemotherapy, imatinib in conjunction with surgical resection has been advocated.[29, 30, 31] Imatinib acts by inhibiting tyrosine kinase enzymes. Several trials have been initiated to explore the role of imatinib as an adjuvant treatment for prolonging disease-free survival, as well as overall survival. Recurrence is a concern after treatment with adjuvant imatinib. Risk factors for GIST recurrence include high tumor mitotic count, nongastric location, large size, rupture, and adjuvant imatinib for 12 months.
Indications and contraindications
Two main indications for surgery exist: diagnosis and treatment. One of the hallmarks of omental tumors is the inability of preoperative studies to identify specific pathologic entities. As noted (see Workup), preoperative fine-needle aspiration (FNA) and core-needle biopsies are controversial for diagnostic purposes in this setting.
With respect to therapy, complete surgical excision (total omentectomy) is the recommended treatment of primary omental tumors. Even when peritoneal implants are present, omentectomy appears to improve survival significantly. Solid omental tumors can also manifest rapidly because of bleeding or intestinal infarction, requiring emergent surgery.
Absolute contraindications for surgical resection include inability to safely resect the tumor because of local invasion.
Most of the surgical procedures do not involve intestinal resections or resection of major organs. As a result, expected postoperative complications mirror those of other clean abdominal procedures. If intestinal resection is performed, the rate of infectious complications increases similar to that of clean-contaminated procedures. Other possible complications include bleeding, pancreatitis, bowel obstruction, and intestinal ischemia.
Recommendations for the follow-up care of patients with solid omental tumors have not been established. Because recurrences and metastases can occur more than 20 years after primary treatments for sarcomas, the authors recommend long-term follow-up care for these patients.
Ishida H, Ishida J. Primary tumours of the greater omentum. Eur Radiol. 1998. 8(9):1598-601. [Medline].
Imachi M, Tsukamoto N, Tsukimori K, Funakoshi K, Nakano H, Shigematsu T, et al. Malignant hemangiopericytoma of the omentum presenting as an ovarian tumor. Gynecol Oncol. 1990 Nov. 39(2):208-13. [Medline].
von Mehren M, Watson JC. Gastrointestinal stromal tumors. Hematol Oncol Clin North Am. 2005 Jun. 19(3):547-64, vii. [Medline].
Kimura H, Maeda K, Konishi K, Tsuneda A, Tazawa K, Earashi M, et al. Primary leiomyosarcoma arising in the lesser sac: report of a case. Surg Today. 1997. 27(7):672-5. [Medline].
Niwa K, Hashimoto M, Hirano S, Mori H, Tamaya T. Primary leiomyosarcoma arising from the greater omentum in a 15-year-old girl. Gynecol Oncol. 1999 Aug. 74(2):308-10. [Medline].
Ishida J, Ishida H, Konno K, Komatsuda T, Abe K. Primary leiomyosarcoma of the greater omentum. J Clin Gastroenterol. 1999 Mar. 28(2):167-70. [Medline].
Rao SR, Rao RS, Sampat MB. Hemangiopericytoma of greater omentum. Indian J Gastroenterol. 2000 Jan-Mar. 19(1):33-5. [Medline].
Shiba H, Misawa T, Kobayashi S, Yokota T, Son K, Yanaga K. Hemangiopericytoma of the greater omentum. J Gastrointest Surg. 2007 Apr. 11(4):549-51. [Medline].
Lipper S, Nunnery EW, Jones KL. Pedunculated fibrosarcoma. Unusual presentation of an intraabdominal fibrosarcoma arising from the greater omentum. Am J Surg. 1980 Sep. 140(3):457-61. [Medline].
Beebe MM, Smith MD. Omental lipoblastoma. J Pediatr Surg. 1993 Dec. 28(12):1626-7. [Medline].
Alam K, Maheshwari V, Sabir F, Haq ME, Siddiqui FA, Mefuzuddin S. Glomus tumor of lesser omentum--a case report. Indian J Pathol Microbiol. 2007 Jul. 50(3):543-4. [Medline].
Naik R, Baliga PB, Pai MR, Nayak KS, Shankarnarayanan. Benign teratoma of the lesser omentum--a case report. Indian J Pathol Microbiol. 2003 Jul. 46(3):461-3. [Medline].
Hertzanu Y, Mendelsohn DB, Murray JF. Leiomyoblastoma of the omentum. A case report. S Afr Med J. 1982 Aug 21. 62(9):297-8. [Medline].
Mahon DE, Carp NZ, Goldhahn RT Jr, Schmutzler RC 3rd. Primary leiomyosarcoma of the greater omentum: case report and review of the literature. Am Surg. 1993 Mar. 59(3):160-3. [Medline].
Matsuo S, Susumu S, Tsutsumi R, Azuma T, Obata S, Hayashi T. Glomus tumor of the omentum: a case report. J Surg Oncol. 2007 Dec 1. 96(7):633-6. [Medline].
Ruan CW, Lee CL, Yen CF, Wang CJ, Soong YK. A huge 6.2 kilogram uterine myoma coinciding with omental leiomyosarcoma: case report. Changgeng Yi Xue Za Zhi. 1999 Dec. 22(4):639-42. [Medline].
Rye BA, Christiansen E, Larsen LG. Acute bleeding from leiomyoblastoma of the greater omentum. A case report. Tumori. 1989 Jun 30. 75(3):296-8. [Medline].
Tsutsumi H, Ohwada S, Takeyoshi I, Izumi M, Ogawa T, Fukusato T, et al. Primary omental liposarcoma presenting with torsion: a case report. Hepatogastroenterology. 1999 May-Jun. 46(27):2110-2. [Medline].
Cao L, Hu X, Zhang Y, Sun XT. Omental milky spots in screening gastric cancer stem cells. Neoplasma. 2011. 58(1):20-6. [Medline].
Miyazawa M, Naritaka Y, Miyaki A, Asaka S, Isohata N, Yamaguchi K, et al. A low-grade myofibroblastic sarcoma in the abdominal cavity. Anticancer Res. 2011 Sep. 31(9):2989-94. [Medline].
Hebra A, Brown MF, McGeehin KM. Mesenteric, omental, and retroperitoneal cysts in children: a clinical study of 22 cases. South Med J. 1993 Feb. 86(2):173-6. [Medline].
O'Brien JG, Allen JE, Queen TA. Leiomyoma of the omentum in a child. J Pediatr Surg. 1986 Nov. 21(11):981-2. [Medline].
Lee JT, Kim MJ, Yoo KS, Suh JH, Leong HJ. Primary leiomyosarcoma of the greater omentum: CT findings. J Comput Assist Tomogr. 1991 Jan-Feb. 15(1):92-4. [Medline].
Kadow C, Amery AH. Primary liposarcoma of the omentum: a rare intra-abdominal tumour. Br J Clin Pract. 1989 Dec. 43(12):460-2. [Medline].
Okajima Y, Nishikawa M, Ohi M, Fukumoto Y, Kuroda K, Shimomukai H. Primary liposarcoma of the omentum. Postgrad Med J. 1993 Feb. 69(808):157-8. [Medline].
Wong PP, Yagoda A. Chemotherapy of malignant hemangiopericytoma. Cancer. 1978 Apr. 41(4):1256-60. [Medline].
Patel Shreyaskumar R, Wong Patrick. Efficacy of Imatinib in Unresectable Gastrointestinal Stromal Tumors. US Oncol Rev. 2009. 5(1):61-4. [Full Text].
Okuno S. The Use of Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumors (GIST). Contemporary Oncol. March 15, 2011. [Full Text].
"News: Genetic Variations in GI Tumors Determine Which Medications Are Efficacious.". Genetic Engineering & Biotechnology News. Nov 2008.
Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, et al. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014 Aug 1. 120 (15):2325-33. [Medline].
|Tumor Histology||Number of Cases||% of Total|
|Spindle cell sarcoma||1||1|
|Malignant fibrous histiocytoma||1||1|
|Gastrointestinal stromal tumor||21||16|